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Abstract 
Social anxiety disorder is a prevalent and impairing disorder for which viable cognitive-behavioral 
therapies exist. However, these treatments have not been easily packaged for dissemination and may 
be underutilized as a result. The current study reports on the findings of a randomized controlled 
trial of a manualized and workbook-driven individual cognitive-behavioral treatment for social anx-
iety disorder (Hope, Heimberg, Juster, & Turk, 2000; Hope, Heimberg, & Turk, 2006). This treatment 
package was derived from an empirically supported group treatment for social anxiety disorder and 
intended for broad dissemination, but it has not previously been subjected to empirical examination 
on its own. As a first step in that examination, 38 clients seeking treatment for social anxiety disorder 
at either the Adult Anxiety Clinic of Temple University or the Anxiety Disorders Clinic of the Uni-
versity of Nebraska–Lincoln were randomly assigned to receive either immediate treatment with 
this cognitive-behavioral treatment package or treatment delayed for 20 weeks. Evaluation at the 
posttreatment/postdelay period revealed substantially greater improvements among immediate 
treatment clients on interviewer-rated and self-report measures of social anxiety and impairment. 
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Three-month follow-up assessment revealed maintenance of gains. Clinical implications and direc-
tions for future research are discussed. 
 
Social anxiety disorder is a highly prevalent and impairing disorder. In the recently com-
pleted National Comorbidity Survey Replication, a lifetime prevalence rate of 12.1% was 
reported (Kessler et al., 2005). In the original National Comorbidity Survey, diagnosis of 
social anxiety disorder was negatively related to educational attainment and income, and 
rates of social anxiety disorder were significantly higher in people who, at the time of the 
study, were not working or in school (Magee, Eaton, Wittchen, McGonagle, & Kessler, 
1996). Social anxiety disorder has also been repeatedly associated with impairment in both 
romantic relationships and friendships (e.g., Antony, Roth, Swinson, Huta, & Devins, 1998; 
Schneier et al., 1994; Whisman, Sheldon, & Goering, 2000). 
Despite the prevalence and impairment associated with social anxiety disorder, most 
people with the disorder do not seek treatment (Erwin, Turk, Heimberg, Fresco, & 
Hantula, 2004; Kessler, Stein, & Berglund, 1998; Olfson et al., 2000). Importantly, when they 
do seek treatment, individuals with social anxiety disorder are unlikely to receive empiri-
cally supported cognitive-behavioral therapies (Goisman, Warshaw, & Keller, 1999; Rowa, 
Antony, Brar, Summerfeldt, & Swinson, 2000). This is unfortunate since the efficacy of cog-
nitive behavioral treatment for social anxiety disorder is well established. Most notably, 
cognitive-behavioral group therapy (CBGT; Heimberg& Becker, 2002) has been thoroughly 
studied. CBGT has been shown to be more efficacious than a control psychotherapy (Heim-
berg et al., 1990; Heimberg et al., 1998) and as efficacious as the monoamine oxidase inhib-
itor, phenelzine (Heimberg et al., 1998). Furthermore, CBGT is associated with lower rates 
of relapse upon treatment discontinuation than phenelzine (Liebowitz et al., 1999). Other 
studies that have employed CBGT, or group treatments similar to it, provide added sup-
port for the efficacy of this treatment approach (e.g., Davidson et al., 2004) and its effec-
tiveness in community and clinical settings as well (Gaston, Abbott, Rapee, & Neary, 2006; 
McEvoy, 2007). 
There has been much discussion about the relative advantages and disadvantages of 
group versus individual treatment for social anxiety disorder (e.g., Huppert, Roth, & Foa, 
2003). Group treatment for social anxiety disorder is inherently sensible since the group 
format provides exposure to much of what clients fear (e.g., casual interaction before the 
group begins, sharing personal information, doing things in front of other people) in a safe, 
therapeutic environment. Heimberg and Becker (2002) identified a number of other ad-
vantages of group treatment, including learning that others have similar problems, the 
opportunity to learn from other members of the group, and encouragement through ob-
servation of others’ successes. 
However, in many clinical settings, group treatment is simply not feasible. In a typical 
clinical practice, it may take several months to gather a sufficient number of clients with 
social anxiety disorder to form a group. Individual treatment may also be better tolerated 
by clients with social anxiety disorder (particularly those with severe symptoms), allows 
the therapist to better tailor treatment to each client’s idiosyncratic concerns, and permits 
flexibility to tailor treatment when clients present with comorbid conditions. Furthermore, 
both meta-analyses (Fedoroff & Taylor, 2001; Gould, Buckminster, Pollack, Otto, & Yap, 
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1997; Powers, Sigmarsson, & Emmelkamp, 2008; Taylor, 1996) and randomized trials (Lu-
cas & Telch, 1993; Scholing & Emmelkamp, 1993) have shown that individual treatment is 
as efficacious as group treatment. In one randomized trial, individual treatment was some-
what more efficacious than group treatment (Stangier, Heidenreich, Peitz, Lauterbach, & 
Clark, 2003). These factors have led to an increasing emphasis on the development of indi-
vidual treatments for social anxiety disorder, but currently these are not widely available 
(e.g., Clark et al., 2003, 2006). 
With these concerns in mind, the current study examined the efficacy of a manualized 
individual treatment for social anxiety disorder. This treatment program, Managing Social 
Anxiety: A Cognitive-Behavioral Therapy Approach, was designed to be easily integrated into 
clinical practice. It includes both a therapist guide (Hope, Heimberg, & Turk, 2006) and a 
client workbook (Hope, Heimberg, Juster, & Turk, 2000). The material included in both the 
therapist guide and client workbook was drawn from the manual for CBGT, which, as 
noted, has been shown to be efficacious and effective in numerous studies (Rodebaugh, 
Holaway, & Heimberg, 2004). No previous empirical examination of this treatment has 
been conducted, and it is important to avoid the assumption that it would be efficacious 
or effective simply because the group treatment from which it was derived has been em-
pirically supported. Furthermore, the client workbook is a new aspect of this treatment, 
making the independent evaluation of this treatment package all the more critical. 
In this study, clients with social anxiety disorder at two study sites were randomly as-
signed to an immediate treatment (IT) condition or to a delayed treatment (DT) condition, 
a control condition selected to best establish the signal strength of this new protocol before 
subjecting it to more rigorous tests or moving toward broader dissemination (see papers 
on this approach by Onken, Blaine, & Battjes, 1997, and Rounsaville, Carroll, & Onken, 
2001). In the initial phase of the study, immediately after completing a baseline assessment, 
clients in the IT condition received 16 sessions of cognitive-behavioral therapy over the 
course of 20 weeks. Twenty weeks were allowed to complete 16 sessions to account for 
issues such as holidays, illness, and vacations that often prevent clients from receiving 16 
consecutive weeks of therapy; thus, some clients in the IT condition completed therapy 
within 16 weeks whereas others took the full 20 weeks to complete 16 sessions. Clients in 
the DT condition began treatment 20 weeks after the baseline assessment. We hypothe-
sized that clients who received immediate treatment would experience greater improve-
ment in social anxiety symptoms than clients who remained on a wait-list for the same 
period of time. We further expected that clients would maintain their gains, or possibly 
show further gains, after a 3-month follow-up period. 
 
Method 
 
Study Design 
Participants initially presented to the Adult Anxiety Clinic of Temple University or the 
Anxiety Disorders Clinic at the University of Nebraska–Lincoln for difficulties with anxi-
ety. At the University of Nebraska, all potential participants underwent an initial evalua-
tion with the Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV; T. Brown, 
DiNardo, & Barlow, 1994), and at Temple, all potential participants underwent the Anxiety 
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Disorders Interview Schedule for DSM-IV, Lifetime Version (ADIS-IV-L; DiNardo, Brown, 
& Barlow, 1994). The ADIS interviews were used to establish diagnoses and determine 
study eligibility. 
Once informed consent was obtained, participants underwent a baseline assessment. 
Following this assessment, participants were randomly assigned to either IT or DT. Clients 
assigned to the DT condition waited 20 weeks to begin treatment but received periodic 
phone check-ins from their assigned clinician in order to monitor their clinical status. 
At the end of the initial 20 weeks of the study, participants underwent another assess-
ment with the same measures used in the baseline assessment. For participants assigned 
to the IT condition, this served as their posttreatment assessment. For participants assigned 
to the DT condition, this served as a metric of how their symptoms had changed during 
their time on the wait-list and an assessment of the severity of their symptoms prior to 
beginning treatment. After their 16 sessions of cognitive-behavioral therapy, they too were 
given a posttreatment assessment, again with the same measures used at the baseline as-
sessment. 
Assessors and therapists were either postdoctoral fellows or doctoral students in clinical 
psychology who were supervised by PhD-level clinicians with expertise in the nature, as-
sessment, and treatment of social anxiety. At Temple, therapists completed at least two 
training cases using the study protocol before treating study cases. Because of the lesser 
flow of potential participants at Nebraska, this was not feasible. There, potential therapists 
were required to view videotapes of D. A. Hope and other highly experienced therapists 
conducting the protocol prior to seeing study cases. Interviewers were trained in the use 
of the ADIS according to standard procedures (T. Brown, DiNardo, Lehman, & Campbell, 
2001). Assessors were uninformed about the condition to which clients had been assigned. 
 
Participants 
Participants were 38 individuals with a principal diagnosis of social anxiety disorder (Tem-
ple n = 21; Nebraska n = 17). Most participants were diagnosed with the generalized type 
of social anxiety disorder (31 participants, 81.6%); the remainder of the sample presented 
with clinically significant fears of public speaking (7 participants, 18.4%). The mean age of 
the sample was 34.87 (SD = 14.73). Participants at Nebraska were significantly older (M = 
41.24) than participants at Temple, M = 29.71, t(36) = –2.57, p < .05. Of the total sample, 22 
(57.9%) were female; site differences on gender did not emerge. The overall sample was 
ethnically diverse: 78.9% of participants were Caucasian, 13.2% African-American, 2.6% 
Hispanic, and 5.3% Asian. However, all ethnic minorities came from the Temple site. The 
majority of the sample was single (55.3%), and most were working at the time of the study. 
A minority (10.5%) of the sample reported that they were unemployed. 
Potential participants were excluded from the study if they met criteria for current sub-
stance dependence, current bipolar disorder, current or past psychotic disorder, or if they 
were suicidal or at imminent risk for engaging in self-harming behaviors. Other comorbid 
conditions were allowed so long as social anxiety disorder was the principal diagnosis. 
Many participants met criteria for additional Axis I diagnoses: 31.58% of participants had 
one additional Axis I diagnosis, and 10.5% of participants had two or more additional Axis 
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I diagnoses. The most common comorbid disorders were dysthymic disorder (n = 7), gen-
eralized anxiety disorder (n = 6), major depressive disorder (n = 5), and specific phobia (n = 3). 
Clients were permitted to be on medication during the study if they had been on a stable 
dose for at least 3 months at the time of study entry and they agreed not to alter their dose 
during the study. Of the 38 participants, 10 (26.3%) reported that they were on medication. 
Four were taking paroxetine, 2 were taking citalopram, and the remaining 4 clients were 
taking buproprion, nefazadone, clonazepam, or imipramine. Eight clients were taking only 
one medication. However, the 2 clients taking citalopram were taking additional medica-
tions, one taking buspirone, and the other taking olanzapine and adderall. Clients were 
not permitted to be in concurrent psychotherapy for anxiety-related concerns. 
 
Measures 
 
Interviewer-Rated Measures 
Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV; T. Brown et al., 1994) and 
Anxiety Disorders Interview Schedule for DSM-IV, Lifetime Version (DSM-IV-L; Di-
Nardo et al., 1994). As noted, the ADIS-IV and the ADIS-IV-L were used to establish the 
diagnosis of social anxiety disorder and any comorbid conditions. Both versions of the 
ADIS are administered and scored in the same way, with one exception—the ADIS-IV-L 
assesses for current and lifetime diagnoses whereas the ADIS-IV assesses only current di-
agnoses. However, only current diagnoses are considered in this study. Hereafter, we refer 
to both the ADIS-IV and the ADIS-IV-L simply as the ADIS. 
The ADIS includes a Clinician’s Severity Rating (CSR) for each diagnosis; the CSR for 
social anxiety disorder served as a major outcome measure in the study. The CSR is a 0- to 
8-point scale, with any score of 4 or above indicating a clinically significant distress and 
impairment warranting the assignment of a DSM-IV (American Psychiatric Association, 
1994) diagnosis. 
Because of procedural differences between the two sites, the social anxiety disorder sec-
tion of the ADIS was administered at both the initial evaluation (i.e., to determine eligibil-
ity) and at the baseline assessment at Temple, but only at the initial evaluation at Nebraska. 
The social anxiety disorder CSR from the initial evaluation therefore served as the pretreat-
ment severity rating for participants in the study. The social anxiety disorder section of the 
ADIS was administered at both sites at all subsequent assessment points to assess change 
in severity of social anxiety symptoms. Clients were also readministered additional mod-
ules of the ADIS for which they met diagnostic criteria at the initial evaluation. 
The psychometric properties of the ADIS are well established. In 362 clients with mixed 
diagnoses, T. Brown et al. (2001) reported a kappa of .77 for a primary diagnosis of social 
anxiety disorder using the ADIS-IV-L. Because the social anxiety disorder module of the 
ADIS was administered at the initial evaluation and at the baseline evaluation at the Tem-
ple site, inter-rater reliability could be calculated. A match was defined as correctly identi-
fying the presence vs. absence of a diagnosis of social anxiety disorder and matching on 
the CSR plus or minus one point, and there was 100% agreement (kappa = 1.0). At Ne-
braska, a second rater reviewed videotapes of a subset of the ADIS interviews conducted 
during the recruitment phase. Using the same criteria, the kappa coefficient was .87. 
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Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987). The LSAS, which is the most 
widely used clinician-administered measure of social anxiety, was the other major social 
anxiety outcome measure used in the study. It includes 24 items, 11 pertaining to social 
interaction situations (e.g., hosting a party) and 13 pertaining to performance situations 
(e.g., making a presentation to a small group). Each item is rated according to the degree 
to which clients have feared and avoided each situation over the past week. The LSAS total 
score was used as the outcome measure in the current study. In a study by Heimberg et al. 
(1999), using data from 382 clients with social anxiety disorder, a mean LSAS total score of 
67.2 (SD = 27.5) was reported. In the current sample, the mean LSAS total score at baseline 
was 68.19 (SD = 22.95). The LSAS has been shown to have strong convergent validity and 
adequate discriminant validity and is sensitive to treatment change (Fresco et al., 2001; 
Heimberg & Holaway, 2007; Heimberg et al., 1999). It is also a highly reliable measure; 
Cronbach’s alphas of .95 and .96 for the LSAS total score have been reported (Fresco et al., 
2001; Heimberg et al.). In the current sample, Cronbach’s alpha for the LSAS total score 
was .95. 
 
Clinical Global Impression Improvement Rating (CGI-I; Guy, 1976). The CGI-I is a 
widely used measure for the assessment of change in treatment. We used a modified ver-
sion of the CGI-I with anchor points developed specifically for rating changes in symptoms 
and impairment associated with social anxiety disorder (Zaider, Heimberg, Fresco, 
Schneier, & Liebowitz, 2003). It is a single item 1–7 rating, with 1 = very much improved, 2 
= much improved, 3 = minimally improved, 4 = no change, and 5–7 representing varying 
degrees of deterioration. This rating was completed at all assessments after baseline upon 
completion of the administration of the ADIS social anxiety disorder module and the LSAS. 
Clients who received a rating of 1 or 2 were classified as responders, and all others were 
classified as nonresponders, in keeping with the traditional use of this instrument. Zaider 
et al. (2003) demonstrated high reliability and validity for this rating at the Temple site. 
 
Self-Report Measures 
Three self-report measures were used to assess the severity of social anxiety symptoms. 
 
Social Interaction Anxiety Scale (SIAS) and the Social Phobia Scale (SPS; Mattick & 
Clarke, 1998). The SIAS measures anxiety in dyads and groups; the SPS measures anxiety 
in situations in which the person may be critically observed by others. Each scale consists 
of 20 items that are rated on a 5-point Likert-type scale from 0 (not at all characteristic) to 4 
(extremely characteristic). Sample SIAS items include, “I feel I will say something embarrass-
ing when talking” and “I have difficulty making eye contact with others.” Sample SPS 
items include, “I get nervous that people are staring at me as I walk down the street” and 
“I worry I might do something to attract the attention of other people.” 
The mean score on the SIAS reported in clinical groups is 50.7 (SD = 17.0) (compared to 
14.3, SD = 11.0 in nonclinical control groups) and the mean score on the SPS is 36.9 (SD = 
17.5) (compared to 6.3, SD = 4.9 in nonclinical control groups; see E. Brown et al., 1997). In 
the current sample, the mean baseline SIAS score was 43.16 (SD = 12.60) and the mean 
baseline SPS score was 32.89 (SD = 15.29). 
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Both the SIAS and the SPS have been shown to be reliable instruments for the assess-
ment of social anxiety disorder and to possess a high degree of convergent validity with 
other indices of social anxiety and avoidance (E. Brown et al., 1997; Heimberg, Mueller, 
Holt, Hope, & Liebowitz, 1992; Mattick & Clarke, 1998). In the current sample, reliability 
was also good, with Cronbach’s alpha of .88 for the SIAS and .92 for the SPS. 
 
Brief Fear of Negative Evaluation Scale (BFNE; Leary, 1983). The BFNE is a 12-item self-
report measure based on Watson and Friend’s (1969) 30-item true-false Fear of Negative 
Evaluation Scale. The BFNE asks participants to read 12 statements and report how char-
acteristic each statement is of them using a 5-point, Likert-type scale. The scale includes 8 
straightforwardly worded items (e.g., “I am frequently afraid of other people noticing my 
short-comings”) and 4 reverse-worded items (e.g., “I am unconcerned even if I know peo-
ple are forming an unfavorable impression of me”). Studies have shown that the straight-
forwardly worded items are more predictive of self-reported anxiety (Rodebaugh et al., 
2004), have higher convergent validity, and are less confusing for participants with lower 
levels of education (Weeks et al., 2005) than the reverse-worded items. Therefore, only the 
8 straightforwardly worded items were summed for a total BFNE score. The entire scale 
was administered. 
In the Weeks et al. (2005) study, the mean score on the 8 positively worded items for 
persons with social anxiety disorder was 30.60 (SD = 6.94), whereas the mean score for a 
nonanxious control group was 12.50 (SD = 4.52). In the current sample, the mean straight-
forward BFNE score at pretreatment was slightly higher, 32.47 (SD = 6.42). In Weeks et al.’s 
sample, the 8-item scale exhibited excellent internal consistency (Cronbach’s alpha = .92), 
as it did in the current sample (Cronbach’s alpha = .91). 
 
Sheehan Disability Scale (SDS; Sheehan, 1983). The SDS served as a measure of impair-
ment as a function of social anxiety disorder and comorbid conditions. The SDS was one 
of the first disability scales to be developed and is the most frequently used disability meas-
ure in the psychiatric literature. Clients are asked to rate their level of impairment in work, 
social life, and family life on a 0 (not at all) to 10 (very severe) scale. Impairment ratings in 
these three areas are summed to provide an overall disability score. 
Hambrick, Turk, Heimberg, Schneier, and Liebowitz (2004) reported on the psychomet-
ric qualities of the SDS and other measures of disability in individuals with social anxiety 
disorder. The mean score on the SDS for clients with generalized social anxiety disorder 
was 16.60 (SD = 5.74) whereas the mean score for clients with nongeneralized social anxiety 
disorder was 11.97 (SD = 5.51). In the current sample, the mean score for all clients (who 
primarily had generalized social anxiety disorder) was 14.11 (SD = 7.06). The SDS corre-
lates with other disability measures, as well as measures of social anxiety, depression, and 
quality of life (Hambrick et al., 2004). The SDS has demonstrated sensitivity to impairment 
across a wide range of disorders (Olfson et al., 1997). In Hambrick et al.’s study, the SDS 
had moderate internal consistency (Cronbach’s alpha of .55) which is not surprising given 
that it has only three items. In the current sample, however, Cronbach’s alpha was .78. 
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Quality of Life Inventory (QOLI; Frisch, Cornell, Villanueva, & Retzlaff, 1992). The 
QOLI, a measure of perceived life satisfaction, requires respondents to make ratings on a 
3-point (0–2) scale of importance and a 6-point (–3 to +3) scale of satisfaction for 16 areas 
of life. Items probe the importance of and satisfaction with life domains such as friend-
ships, romantic relationships, career, and self-esteem. Total scores are based upon the av-
erage of one’s satisfaction with all 16 areas of life, weighted for the individual importance 
of those areas of life. 
In a study by Eng, Coles, Heimberg, and Safren (2001), the mean score on the QOLI 
among clients with social anxiety disorder was 0.41 (SD = 1.41). The mean in the current 
sample was 0.34 (SD = 1.67). The QOLI is positively correlated with other widely used 
measures of subjective well-being and life satisfaction and negatively related to measures 
of depression, anxiety, and general psychopathology (Eng et al., 2001; Safren, Heimberg, 
Brown & Holle, 1997). Retest reliability (r = .80–.91) and internal consistency of the QOLI 
(α = .98) are high (Frisch et al., 1992). In the current study, Cronbach’s alpha was .82. 
 
Treatment Conditions 
 
Immediate Treatment (IT) Condition (n = 16) 
Immediately after completing the baseline assessment, clients in the IT condition began 
treatment, which consisted of 16 sessions completed within 20 weeks. All sessions lasted 
for 1 hour, except for the session in which the first in-session exposure was conducted, 
which lasted 1.5 hours. The content of the treatment was guided by the client workbook 
(Hope et al., 2000) and consists of five major components: (1) psychoeducation and orien-
tation to CBT; (2) cognitive restructuring skills; (3) graduated exposure to feared social 
situations, both within the treatment session and as homework for exposure in the client’s 
environment; (4) examination and modification of core beliefs; and (5) relapse prevention 
and termination. Readings in the client workbook were assigned prior to sessions. The 
structure of the treatment allowed for some flexibility depending on the client. Generally, 
up to four sessions were allotted for the initial four chapters of the workbook, which in-
cluded psychoeducational material about social anxiety, an introduction to the treatment 
rationale, and development of the fear and avoidance hierarchy. Up to three sessions could 
be spent on cognitive restructuring skills (e.g., teaching clients to identify and challenge 
automatic thoughts). The first in-session exposure had to occur at or before Session 8, and 
treatment then proceeded for the next several sessions with weekly in-session exposures 
and accompanying cognitive restructuring as well as assignment of homework for in vivo 
exposures to be completed prior to the following session. The expectation was that all cli-
ents would do at least four in-session exposures. Parts of later sessions were also dedicated 
to advanced cognitive restructuring in which core beliefs were examined. During the last 
two sessions, as termination approached, relapse prevention was discussed. Further de-
tails are available in Hope et al. (2000, 2006). 
 
Delayed Treatment (DT) Condition (n = 22) 
Immediately after completing the baseline assessment, clients in the DT condition began a 
20-week wait period. At the beginning of this period, they were assigned a therapist and 
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brief biweekly telephone contacts were arranged. The purpose of these calls was to check 
on the client’s clinical status and provide support. Use of specific treatment interventions 
(e.g., cognitive restructuring, suggestions to do exposure) was not permitted. Clients were 
encouraged to call their therapists if they were having difficulties or believed that they 
required immediate clinical attention. None of the clients who were assigned to the DT 
condition were withdrawn because of concern about their clinical status. 
At the completion of 20 weeks, clients in the DT condition underwent an evaluation 
which, as noted above, served as a metric of how their symptoms had changed during their 
time on the wait-list and the severity of their symptoms prior to beginning treatment. At 
this point, they began 20 weeks (16 sessions) of CBT and then completed a posttreatment 
assessment. 
 
Therapy Adherence 
A Therapist Adherence Scale was developed and tested over the course of this study. This 
scale (available from the authors) required that raters evaluate the extent to which several 
different therapy activities had been implemented in a manner that was maximally con-
sistent with the intent of the therapy manual. As noted above, the course of therapy was 
divided into five segments. Ratings were performed on 31 session tapes (17 from Temple 
and 14 from Nebraska), randomly selected from the five phases of the protocol. Within 
each phase, several ratings were required, and specific criteria were articulated to facilitate 
the process. The ratings were made on a 1-to-5 scale, ranging from 1 (ineffective) to 5 (ex-
tremely effective). A rating of 4 (reasonably effective) or 5 (extremely effective) was considered 
to be within protocol. 
Tapes were coded by two independent judges who were doctoral students in clinical 
psychology at the Nebraska site. Both judges rated tapes from 18 sessions (6 from Temple; 
12 from Nebraska) in common and achieved an intraclass correlation of ri = .82, suggesting 
good interrater agreement. Overall, therapists were well within protocol, achieving an av-
erage overall rating of 4.44 (SD = 0.78) across sites. 
 
Results 
 
Attrition 
Of the 22 clients assigned to the delayed treatment condition, 3 dropped during the wait 
period and did not provide postdelay data. Of the 16 clients assigned to the immediate 
treatment condition, all but 1 completed treatment and provided posttreatment data. 
Both intent-to-treat (ITT) and completer analyses were performed. For the ITT analyses, 
participants’ last observation was carried forward. For participants in the delayed treat-
ment condition, this meant carrying forward their pretreatment evaluation to the postde-
lay time point. For participants in the immediate treatment condition, this meant carrying 
forward the pretreatment evaluation to the posttreatment time point. Completer and ITT 
analyses yielded virtually identical findings. Therefore, only the completer analyses are 
reported here. ITT analyses are available on request. 
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Between-Group Analyses 
There were no significant differences between the IT and DT groups on any measure at the 
baseline assessment. Main hypotheses were evaluated using univariate analysis of covariance 
with treatment condition as the independent variable (immediate treatment versus de-
layed treatment) and the posttreatment or postdelay measure of interest as the dependent 
variable. The baseline score (pretreatment/predelay) on the measure of interest was used 
as a covariate. These analyses were first conducted with site (Temple vs. Nebraska) as an 
additional independent variable. No main effects of site and only one site-by-treatment-
condition interaction was significant. Across analyses, inclusion of site effects resulted in 
larger main effects for condition. Therefore, we report (with the one exception) the more 
straightforward analyses without site. The site-by-treatment-condition analyses are avail-
able on request. 
 
Interviewer-Rated Measures 
Table 1 displays means, standard deviations, and effect sizes for all interviewer-rated and 
self-report measures. At the 20-week assessment, participants in the IT condition received 
significantly lower ADIS CSR ratings than participants in the DT condition, F(1, 32) = 13.29, 
p < .001. This main effect was qualified by the one significant site-by-treatment interaction, 
F(1, 32) = 6.27, p < .02. Posttreatment/postdelay means adjusted for baseline demonstrated 
a tendency for greater improvement on this rating at the Nebraska site. However, the 95% 
confidence intervals around these means overlapped, suggesting that specific pairwise 
comparisons were not significant. Clients who completed the IT condition received signif-
icantly lower scores on the LSAS at the 20-week assessment than clients who completed 
the DT condition. Of the 31 clients for whom the CGI-I was completed, 11/15 (73.3%) par-
ticipants in the IT condition were classified as responders on the CGI-I, compared to 1 
(6.3%) client of 16 in the DT condition, χ2(1, N = 31) = 14.69, p < .001. 
At posttreatment assessments, ADIS modules for which clients met diagnosis at pre-
treatment were readministered and CSR ratings were made. Of the 11 clients who met 
criteria for at least one additional Axis I disorder at baseline and who completed the post-
treatment/postdelay assessment, 4 (36.36%) no longer met criteria for their additional di-
agnoses by the latter assessment, despite the fact that therapy only targeted the symptoms 
of social anxiety disorder. Three of these 4 clients had an additional diagnosis of general-
ized anxiety disorder; 1 of these clients also had co-occurring dysthymia. The other client 
had a specific phobia. Interestingly, the client with both generalized anxiety disorder and 
dysthymia lost both of these diagnoses by the end of treatment. 
 
Self-Report Measures 
Three social anxiety self-report measures were administered in the study: the BFNE, the 
SIAS, and the SPS. At the 20-week assessment, clients in the IT condition scored signifi-
cantly lower on all of these measures than clients who completed the DT condition (see 
Table 1). 
Two measures were administered to assess for disorder-related impairment, the SDS 
and the QOLI. At the 20-week assessment, clients who were assigned to the IT condition 
reported significantly less disability (SDS) than clients who completed the DT condition 
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(see Table 1). Clients who completed the IT condition also reported slightly better quality 
of life than those in the DT condition; this trend resulted in a moderate effect size (all other 
analyses reported above resulted in large effect sizes per the criteria outlined by Cohen, 
1988; see Table 1), but did not reach the level of statistical significance. 
 
Table 1. Pretreatment scores and posttreatment/postdelay scores on study measures 
Measure 
Estimated Marginal 
Mean at Pretreatment 
(nonadjusted mean and 
standard deviation in 
parentheses) 
Treatment 
condition 
Posttreatment 
or Postdelay F 
Cohen’s 
d 
Interviewer Rated Measures     
ADIS Clinician 
   Severity Rating for 
   social anxiety 
   disorder 
5.61 (5.61, SD = 0.95) Immediate 
Delayed 
3.92 (SE = 0.29) 
5.24 (SE = 0.27) 
10.90** 1.21 
Liebowitz Social 
   Anxiety Scale 
67.71 (68.19, SD = 22.95) Immediate 
Delayed 
46.81 (SE = 5.23) 
62.98 (SE = 4.71) 
4.86* 0.83 
Self-Report Measures: Social Anxiety     
Brief Fear of Negative 
   Evaluation Scale 
   (8-item) 
32.52 (32.47, SD = 6.42) Immediate 
Delayed 
21.30 (SE = 1.47) 
31.23 (SE = 1.33) 
23.80*** 1.84 
Social Phobia Scale 32.90 (32.89, SD = 15.29) Immediate 14.64 (SE = 2.52) 27.70*** 1.99 
  Delayed 32.71 (SE = 2.29)   
Social Interaction 
   Anxiety Scale 
42.70 (43.16, SD = 12.60) Immediate 
Delayed 
27.63 (SE = 1.77) 
45.89 (SE = 1.65) 
55.94*** 2.88 
Self-Report Measures: Disability and Quality of Life    
Sheehan Disability 
   Scale 
14.26 (14.11, SD = 7.06) Immediate 
Delayed 
8.66 (SE = 1.10) 
14.26 (SE = 1.06) 
13.17** 1.37 
Quality of Life 
   Inventory 
0.53 (0.34, SD = 1.67) Immediate 
Delayed 
1.19 (SE = 0.33) 
0.63 (SE = 0.33) 
1.50 0.51 
Note: ADIS = Anxiety Disorders Interview Schedule; SD = Standard Deviation; SE = Standard Error of Meas-
urement. F-test is for the main effect for condition (immediate vs. delayed treatment) in a one-way analysis of 
covariance. See text for report of the significant site-by-treatment-condition interaction in preliminary analysis 
for the ADIS Clinician’s Severity Rating. Cohen’s d is calculated as the differences in means between clients 
receiving immediate and delayed treatment divided by the pooled SD; a d of 0.20 is considered small, 0.50 is 
considered moderate; and 0.80 is considered large (Cohen, 1988). 
* p < .05 
** p < .01 
*** p < .001 
 
Within-Group Analyses 
Paired-sample t-tests were conducted separately for IT and DT participants to examine the 
degree to which they demonstrated significant within-group change. The IT group demon-
strated significant pretreatment to posttreatment change on six of the seven outcome var-
iables, the lone exception being the QOLI. Within-group effect sizes (d) ranged from 1.03 
to 5.22, with a median of 2.52 and a mean of 2.98. The DT group demonstrated significant 
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change on only one measure, the SIAS, and that test revealed a significant increase in social 
interaction anxiety. Five of seven effect sizes were small (< 0.36), and three of seven de-
noted modest change in the direction of increased anxiety and impairment. Details of these 
analyses are available from the authors. 
 
Follow-up Analyses 
Clients underwent another assessment 3 months posttreatment. Only 12 clients (35% of the 
completer sample) completed the follow-up independent evaluation. Clients who com-
pleted the follow-up evaluation were compared to clients who did not complete the eval-
uation on pre- and post-treatment ADIS clinician’s severity ratings and on pre- and post-
treatment LSAS scores. The two groups did not differ significantly on any of these measures. 
A greater proportion of clients who completed the follow-up evaluation had originally 
been assigned to the IT group (8/12, 66.6%). However, these analyses are performed on 
clients who had completed treatment, either immediate or delayed, who were combined 
for these analyses. Because some of these clients did not return self-report measures at 
follow-up, the present analyses focus only on the ADIS clinician’s severity rating and the 
LSAS (interviewer-rated measures). 
Paired sample t-tests were run comparing scores at pretreatment and follow-up. For 
both the ADIS rating and the LSAS, clients showed significant improvements from pre-
treatment to follow-up (both ps < .001). However, t-tests comparing posttreatment to fol-
low-up scores were not significant, suggesting maintenance of gains but no further change 
during the follow-up interval. 
 
Discussion 
 
The current study evaluated the efficacy of a manualized individual therapy program 
(Hope et al., 2000, 2006). Data from this study indicate that the Managing Social Anxiety 
program was efficacious. At posttreatment, clients who received treatment showed signif-
icantly greater improvement in their social anxiety symptoms and were more likely to be 
classified as treatment responders than clients who were assigned to the DT condition. 
Furthermore, clients who received treatment showed significant reduction in disorder-
related disability and a trend toward improvement in quality of life compared to clients 
who were assigned to the DT condition. Large effect sizes were the rule in these analyses. 
Of the clients from whom we were able to collect follow-up data, gains were maintained 
for at least 3 months. 
This study is not without limitations. First, it was carried out by the group who authored 
the treatment manual being studied. However, potential biases were reduced by employ-
ing a control group matched on time and using raters uninformed about condition assign-
ment to assess change over the course of treatment. Second, treatment was carried out by 
postdoctoral fellows and doctoral candidates under the supervision of PhD-level clinicians 
who are experts in social anxiety (including two of the authors of the manual) and thus 
provides no information about how clients would respond to the program when treated 
by clinicians in the community, and research on that topic is warranted. Clinicians in the 
community likely have more general experience than many of the clinicians in the current 
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study, but they may have less expertise in the treatment of clients with social anxiety dis-
order or in the specific behaviors required of the therapist in this protocol. This concern is 
partially addressed by the availability of a therapist guide as a supplement to this treat-
ment program. Third, our sample was relatively small, particularly for the evaluation of 
maintenance of gains. Despite the small sample, however, group differences appeared to 
be robust. Fourth, site-by-treatment-condition interactions were generally not an issue, 
with only one (ADIS clinician’s severity rating) significant; however, the effects of site (e.g., 
related to age and ethnicity) and site-by-treatment-condition interactions could not be fully 
evaluated. Finally, the treatment program was compared to a wait-list control group. 
Therefore, we cannot comment on how this treatment program compares to other active 
treatments like medication, a control psychotherapy (like the educational supportive ther-
apy used in Heimberg et al., 1990; 1998), or another psychotherapy like Acceptance and 
Commitment Therapy (see Eifert & Forsyth, 2005). 
Our hope is that this study will spur future research. Flowing from the limitations just 
noted, future studies should include larger samples (particularly to ensure better follow-
up data) and comparison to more sophisticated control conditions and active treatments. 
Most importantly, we need to study the effectiveness of this treatment under less con-
trolled conditions in the community and ultimately disseminate it to mental health profes-
sionals for treatment of clients with social anxiety disorder, as this was the purpose for 
which this protocol was developed. 
It is also important to examine the efficacy of the treatment when used by clients as a 
self-help manual. It would be interesting to study the efficacy of the client workbook with 
variable amounts of therapist involvement (e.g., no therapist involvement/self-help, peri-
odic therapist assistance by phone/email, and therapist guided as in the current study). A 
study of this nature could involve randomly assigning clients to a treatment condition or 
could take a stepped-care approach in which all clients begin with no therapist involve-
ment, but then receive increasing therapist involvement if their symptoms do not improve 
after varying time periods (a similar study was done in clients with obsessive-compulsive 
disorder; see Tolin et al., 2007; Tolin, Diefenbach, Maltby, & Hannan, 2005). Rapee, Abbott, 
Baillie, and Gaston (2007) recently demonstrated better response to a self-help program for 
social anxiety disorder when therapist assistance was a part of the program. 
To summarize, an individual treatment program based on an efficacious and effective 
group therapy for social anxiety disorder was shown to be more efficacious than no treat-
ment in reducing the symptoms and impairment associated with this chronic disorder. 
Treatment gains appear to be durable for at least 3 months posttreatment, although further 
evaluation is required with larger samples. Given that individual treatment is much more 
feasible than group treatment in most clinical settings, the wide availability of this treat-
ment protocol should help facilitate dissemination of this evidence-based treatment. Fu-
ture research should further examine the utility of this treatment program, particularly as 
it pertains to dissemination to community clinicians. 
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